文献速递耳科与耳神经

纤维蛋白原变化与全频下降型突发性聋疗效的相关性

[Correlation between the changes of fibrinogen and the treatment effect of all-frequency sudden deafness].
PubMed 文献 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2018-01-01

该回顾性研究纳入148例全频下降型突发性聋患者,均接受标准治疗并规律使用巴曲酶,监测治疗第1、3、7±1、14±2天纤维蛋白原,分析其与疗效的相关性。结果显示治疗前纤维蛋白原<2 g/L或>4 g/L时疗效最差,治疗第3天纤维蛋白原波动于0.7~0.9 g/L时疗效最好,第7天纤维蛋白原<1 g/L时疗效最好且对疗效有预测价值。

要点

  • 治疗前纤维蛋白原<2 g/L或>4 g/L时无效 rate 均为50%。
  • 治疗第3天纤维蛋白原最低,波动于0.7~0.9 g/L时总有效率73.9%~83.3%。
  • 治疗第7天纤维蛋白原<1 g/L时疗效最好,值越高无效风险越高。

核心结论

  • 全频下降型突发性聋患者治疗过程中纤维蛋白原的变化与疗效密切相关。

研究设计与样本

  • 回顾性研究,纳入2010年1月至2016年9月北京大学人民医院耳鼻咽喉科住院的全频下降型突发性聋患者148例。
  • 所有患者接受标准治疗方案且规律使用巴曲酶,监测治疗第1天(用药前)、第3天、第(7±1)天及第(14±2)天的外周血纤维蛋白原。
  • 收集治疗前及第(14±2)天纯音测听,分析纤维蛋白原变化与疗效的相关性。
  • 采用独立样本t检验分析正态分布计量资料,卡方线性趋势检验分析不同纤维蛋白原组疗效。

主要发现

  • 治疗前纤维蛋白原<2 g/L或>4 g/L时疗效最差,无效 rate 均为50%。
  • 治疗第3天纤维蛋白原为最低值,波动于0.7~0.9 g/L时总有效率73.9%~83.3%。
  • 治疗第7天纤维蛋白原对疗效有预测价值,有效组Fib7显著低于无效组[(1.25±0.37)g/L vs (1.38±0.35)g/L,t=-0.27,P=0.04]。
  • Fib7<1 g/L时疗效最好,Fib7越高无效风险越高(χ²=7.55,P=0.01)。
  • 治疗第(14±2)天纤维蛋白原整体较高;巴曲酶安全性较好,无鼻腔、口腔、消化道出血或全身出血倾向。

关键数值与推荐

  • 治疗前纤维蛋白原<2 g/L或>4 g/L时无效 rate 均为50%。
  • 治疗第3天纤维蛋白原波动于0.7~0.9 g/L时总有效率73.9%~83.3%。
  • 治疗第7天Fib7<1 g/L时疗效最好,Fib7越高无效风险越高(χ²=7.55,P=0.01)。
  • 有效组与无效组Fib7分别为(1.25±0.37)g/L与(1.38±0.35)g/L(t=-0.27,P=0.04)。

临床怎么用

  • 治疗前可检测纤维蛋白原,<2 g/L或>4 g/L提示疗效可能较差。
  • 治疗第3天纤维蛋白原波动于0.7~0.9 g/L时疗效较好。
  • 治疗第7天纤维蛋白原<1 g/L提示疗效较好,可作为预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the correlation between the changes of fibrinogen and the treatment effect of all-frequency sudden deafness, and to explore the individualized treatment strategy for the use of Batroxobin. Methods: Patients with all-frequency sudden deafness who were admitted to Department of Otorhinolaryngology, People's Hospital of Peking University, from January 2010 to September 2016 were selected. All patients were given standard treatment and regular use of Batroxobin. Value of fibrinogen on D1 (before treatment) / D3 / D7 (±1) and D14 (±2) were recorded, at the same time, the correlation between the changes of fibrinogen and prognosis of all-frequency sudden deafness by the audiograms of onset and after-treatment of all patients were analyzed. Independent t-test was used to analyze normal distributed measurement data and chi square linear trend test was used to analyze the curative effect of different fibrinogen groups. Results: A total of 148 patients were included, the outcomes were worst when the patient's fibrinogen was below 2 g/L or above 4 g/L before treatment, ineffective rate were both 50%. The fibrinogen was lowest when the treatment came to the third day. Normally, the patient's prognosis was best when this value waved between 0.7 and 0.9 g/L, with a total effective rate between 73.9% and 83.3%. The fibrinogen value of the 7th day was a good indicator of the outcome, and Fib7 value was significant lower in patients of effective group than ineffective ones ((1.25±0.37)g/L vs (1.38±0.35) g/L, t=-0.27, P=0.04). Patients found a best recovery when Fib7 was below 1 g/L, and the higher the Fib7 value, the higher the inefficiency (χ(2)=7.55, P=0.01). Batroxobin showed safety during the treatment and found no complications. Conclusion: The change of fibrinogen in the process of all-frequency sudden deafness is closely related to the curative effect. 目的: 通过分析全频下降型突发性聋患者治疗期间纤维蛋白原的变化与疗效的相关性,探讨巴曲酶个性化用药的可行性。 方法: 选取2010年1月至2016年9月于北京大学人民医院耳鼻咽喉科住院治疗的全频下降型突发性聋患者共148例进行回顾性研究,所有患者均接受标准治疗方案且规律使用巴曲酶,监测其治疗第1天(用药前)、第3天、第(7±1)天及第(14±2)天的外周血纤维蛋白原,同时收集患者治疗前、第(14±2)天的纯音测听,分析纤维蛋白原值的变化与疗效的相关性。 结果: 治疗前患者的纤维蛋白原<2 g/L或>4 g/L时,其疗效较差。治疗第3天时,纤维蛋白原为最低值,其波动于0.7~0.9 g/L时疗效最好。治疗第(7±1)天时的纤维蛋白原对疗效有预测价值,其<1 g/L时疗效最好。治疗第(14±2)天时,纤维蛋白原整体较高。整个治疗过程中,巴曲酶安全性较好,无鼻腔、口腔、消化道出血或全身出血倾向。 结论: 全频下降型突发性聋患者治疗过程中纤维蛋白原的变化与疗效密切相关。.

来源:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Fang X, Yu LS, Ma X, et al. [Correlation between the changes of fibrinogen and the treatment effect of all-frequency sudden deafness]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018. PMID: 29365372. doi:10.3760/cma.j.issn.1673-0860.2018.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。